Smoking Cessation for People Living With HIV/AIDS
Last updated on April 2022Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 400
Inclusion Criteria
- Patient enrolled in the HIV clinic with HIV or AIDS diagnosis
- Age 18 years or older
- Able to read and understand English
- ...
- Patient enrolled in the HIV clinic with HIV or AIDS diagnosis
- Age 18 years or older
- Able to read and understand English
- Smoke more than 10 cigarettes/day
Exclusion Criteria
- Are already participating in other smoking cessation interventions.
- Are in recovery for pathological gambling (PG)
- Have contraindications for bupropion treatment (e.g., presence of epilepsy or other seizure disorder, use of monoamine oxidase inhibitors or other antidepressants, presence of eating disorders or very low weight)
- ...
- Are already participating in other smoking cessation interventions.
- Are in recovery for pathological gambling (PG)
- Have contraindications for bupropion treatment (e.g., presence of epilepsy or other seizure disorder, use of monoamine oxidase inhibitors or other antidepressants, presence of eating disorders or very low weight)
- Are actively suicidal or have uncontrolled manic or psychotic symptoms requiring immediate care
Summary
- Conditions
- AIDS
- HIV
- Nicotine Dependence
- Type
- Interventional
- Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
All research related activities will take place at the Tolan Park Medical Building located at 3901 Chrysler Service Dr, Detroit, 48201. Participants in Phase 1 will be randomized to one of two brief interventions based on standard of care guidelines (SoC): A) brief counseling and bupropion (SoC); or...
All research related activities will take place at the Tolan Park Medical Building located at 3901 Chrysler Service Dr, Detroit, 48201. Participants in Phase 1 will be randomized to one of two brief interventions based on standard of care guidelines (SoC): A) brief counseling and bupropion (SoC); or B) SoC plus brief high-magnitude prize CM (HM-CM). At the end of Phase 1, participants will be classified as responders or non-responders on the basis of smoking reduction/abstinence. All participants will continue to receive bupropion. Non-responders will enter Phase 2a and be randomly assigned to: A) continued counseling and monitoring support to quit smoking (MS); or B) MS plus prize CM for abstinence (MS+CM). Phase 1 responders will be entered into Phase 2b and randomly assigned to: A) no additional treatment (NAT); or B) Continued monitoring and low intensity prize CM (LI-CM). The primary dependent variables will include cotinine and carbon monoxide (CO) levels, and longest duration of abstinence from cigarettes. Seven-day point prevalence will be used to assess outcome at post-treatment, 6-month and 12-month follow-up points. Participants will be paid $35 for intake and $25 for each follow-up interview, which will occur at post-phase 1, post-phase 2, and 6-months and 12-months after treatment initiation. Some assessments as well as treatment sessions will be recorded to ensure data quality.
Inclusion Criteria
- Patient enrolled in the HIV clinic with HIV or AIDS diagnosis
- Age 18 years or older
- Able to read and understand English
- ...
- Patient enrolled in the HIV clinic with HIV or AIDS diagnosis
- Age 18 years or older
- Able to read and understand English
- Smoke more than 10 cigarettes/day
Exclusion Criteria
- Are already participating in other smoking cessation interventions.
- Are in recovery for pathological gambling (PG)
- Have contraindications for bupropion treatment (e.g., presence of epilepsy or other seizure disorder, use of monoamine oxidase inhibitors or other antidepressants, presence of eating disorders or very low weight)
- ...
- Are already participating in other smoking cessation interventions.
- Are in recovery for pathological gambling (PG)
- Have contraindications for bupropion treatment (e.g., presence of epilepsy or other seizure disorder, use of monoamine oxidase inhibitors or other antidepressants, presence of eating disorders or very low weight)
- Are actively suicidal or have uncontrolled manic or psychotic symptoms requiring immediate care
Tracking Information
- NCT #
- NCT01965405
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Investigators
- Principal Investigator: David Ledgerwood, PhD Wayne State University
- David Ledgerwood, PhD Wayne State University